{"id":2028,"date":"2021-10-22T18:01:55","date_gmt":"2021-10-22T18:01:55","guid":{"rendered":"https:\/\/www.awkolaw.com\/?page_id=2028"},"modified":"2023-06-16T15:49:49","modified_gmt":"2023-06-16T15:49:49","slug":"belviq-lawsuit","status":"publish","type":"page","link":"https:\/\/www.awkolaw.com\/litigation-areas\/defective-drugs\/belviq-lawsuit\/","title":{"rendered":"Belviq"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”gcid-240a9ec6-8ca4-46e7-b795-ccc98c8b36c4″ use_background_color_gradient=”on” background_color_gradient_direction=”352deg” background_color_gradient_stops=”gcid-240a9ec6-8ca4-46e7-b795-ccc98c8b36c4 45%|#ffffff 100%” background_color_gradient_start=”gcid-240a9ec6-8ca4-46e7-b795-ccc98c8b36c4″ background_color_gradient_start_position=”45%” background_color_gradient_end=”#ffffff” background_enable_image=”off” background_size=”contain” background_position=”center_left” global_colors_info=”{%22gcid-240a9ec6-8ca4-46e7-b795-ccc98c8b36c4%22:%91%22background_color%22,%22colorStart%22%93}”][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][dsm_block_reveal_text block_reveal_text=”Belviq Lawsuit” heading_html_tag=”h1″ block_reveal_color=”gcid-546ba48d-cfd8-4b8f-9a94-622a690b5247″ _builder_version=”4.20.4″ _module_preset=”default” header_font=”Merriweather||||||||” header_text_color=”gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9″ header_font_size=”36px” header_line_height=”1.3em” custom_margin=”||16px|25px|false|false” global_colors_info=”{%22gcid-546ba48d-cfd8-4b8f-9a94-622a690b5247%22:%91%22block_reveal_color%22%93,%22gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9%22:%91%22header_text_color%22%93}”][\/dsm_block_reveal_text][dsm_block_reveal_text block_reveal_text=”Diet Drug Belviq Removed From Market Due To Cancer Risk” block_reveal_color=”gcid-546ba48d-cfd8-4b8f-9a94-622a690b5247″ _builder_version=”4.20.4″ _module_preset=”default” header_font=”||||||||” header_text_color=”gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9″ header_line_height=”1.3em” custom_margin=”|||25px|false|false” global_colors_info=”{%22gcid-546ba48d-cfd8-4b8f-9a94-622a690b5247%22:%91%22block_reveal_color%22%93,%22gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9%22:%91%22header_text_color%22%93}”][\/dsm_block_reveal_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”#evaluation” button_text=”FREE CASE EVALUATION” _builder_version=”4.16″ _module_preset=”default” custom_button=”on” button_text_color=”gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9″ button_border_color=”#FFAF02″ custom_margin=”10px||||false|false” global_colors_info=”{%22gcid-546ba48d-cfd8-4b8f-9a94-622a690b5247%22:%91%22button_bg_color%22,%22button_bg_color%22%93,%22gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9%22:%91%22button_text_color%22%93}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”40px|||||” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.4″ _module_preset=”default” custom_margin=”0px||||false|false” custom_padding=”0px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.4″ _module_preset=”default” custom_padding=”25px|25px|25px|25px|false|true” global_colors_info=”{}”]<\/p>\n

The results of a recent clinical trial show that the diet drug Belviq (lorcaserin) is linked to an increased risk of developing cancer. Drug manufacturer Eisai Inc. has \u201csubmitted a request to voluntarily withdraw the drug\u201d according to Dr. Janet Woodcock, Director of the FDA\u2019s Center for Drug Evaluation and Research.<\/span><\/p>\n

Now, \u201cwe\u2019re taking steps to notify the public,\u201d she added, stating that \u201cour review of the full clinical trial results shows that the potential risk of cancer associated with the drug outweighs the benefit of treatment.\u201d<\/span><\/p>\n

The agency stated that \u201cpatients should stop using the medication Belviq and Belviq XR [lorcaserin] and talk to their health care professionals about other treatment options for weight loss. Health care professionals should stop prescribing and dispensing Belviq and Belviq XR.\u201d<\/span><\/p>\n

The agency first announced that Belviq might have links to cancer in a communication issued Jan 15, 2020.<\/span><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.17.1″ _module_preset=”default” background_color=”gcid-240a9ec6-8ca4-46e7-b795-ccc98c8b36c4″ background_enable_color=”on” global_colors_info=”{%22gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9%22:%91%22header_2_text_color%22%93,%22gcid-240a9ec6-8ca4-46e7-b795-ccc98c8b36c4%22:%91%22background_color%22%93}”]<\/p>\n

What is Belviq?<\/h2>\n

Belviq was approved by the FDA in 2012 for use as an add-on therapy to help aid weight loss, along with diet and exercise, in people who were obese or overweight. Belviq increases feelings of fullness so that people eat less. It\u2019s available as a tablet (Belviq) and an extended-release tablet (Belviq XR).<\/span><\/p>\n

[\/et_pb_text][et_pb_text ul_type=”square” _builder_version=”4.17.6″ _module_preset=”default” ul_font_size=”16px” global_colors_info=”{%22gcid-b3bc4740-83c0-49fc-94f2-b1bc7d48ace9%22:%91%22header_2_text_color%22%93}”]<\/p>\n

Injuries Associated With Belviq<\/h2>\n

The FDA ordered a randomized, placebo-controlled trial be conducted involving 12,000 people tracked for more than five years.\u201d A range of cancer types was reported,\u201d the FDA said. \u201cSeveral different types of cancers occurred more frequently among patients treated with Belviq, including:\u00a0<\/span><\/p>\n